Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Sarepta Therapeutics Inc Stock Research

SRPT

119.55USD+1.58(+1.34%)Market Closed
Watchlist

Market Summary

USD119.55+1.58
Market Closed
1.34%

SRPT Alerts

  • 1 major insider buys recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

SRPT Stock Price

SRPT RSI Chart

SRPT Valuation

Market Cap

11.2B

Price/Earnings (Trailing)

-12.29

Price/Sales (Trailing)

11.11

EV/EBITDA

-12.6

Price/Free Cashflow

-20.94

SRPT Price/Sales (Trailing)

SRPT Profitability

EBT Margin

-112.59%

Return on Equity

-156.47%

Return on Assets

-36.45%

Free Cashflow Yield

-4.78%

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

1.0B

Revenue Y/Y

11.89%

Revenue Q/Q

3.05%

SRPT Earnings

Earnings (TTM)

-907.7M

Earnings Y/Y

89.66%

Earnings Q/Q

95.37%

Price Action

52 Week Range

159.89
(Low)(High)

Last 7 days

-0.1%

Last 30 days

5.1%

Last 90 days

4.8%

Trailing 12 Months

8.5%

SRPT Financial Health

Current Ratio

4.63

SRPT Investor Care

Shares Dilution (1Y)

6.58%

Diluted EPS (TTM)

-10.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SRPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-14
Chambers Michael Andrew
bought
1,092,430
109
9,979
-
2023-08-11
Chambers Michael Andrew
bought
2,559,270
108
23,686
-
2023-08-10
Chambers Michael Andrew
bought
3,701,070
106
34,867
-
2023-08-04
Wigzell Hans Lennart Rudolf
acquired
435,450
29.03
15,000
-
2023-08-04
Wigzell Hans Lennart Rudolf
sold
-1,600,800
106
-15,000
-
2023-06-01
Brown Ryan Edward
sold (taxes)
-11,000
123
-89.00
evp, general counsel
2023-03-30
Arif Bilal
sold (taxes)
-41,954
136
-307
chief tech ops officer
2023-03-08
Rodino-Klapac Louise
sold (taxes)
-139,709
153
-912
head of r&d, cso
2023-03-08
Arif Bilal
sold (taxes)
-48,101
153
-314
chief tech ops officer
2023-03-08
Brown Ryan Edward
sold (taxes)
-97,275
153
-635
svp, general counsel

1–10 of 50

Which funds bought or sold SRPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-13
CGC Financial Services, LLC
new
-
104,557
104,557
0.07%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
-443
2,176
-%
2023-08-29
EFG Asset Management (Americas) Corp.
added
16.23
-8,219
231,330
0.05%
2023-08-25
Yarbrough Capital, LLC
new
-
319,511
319,511
0.02%
2023-08-24
PERCEPTIVE ADVISORS LLC
reduced
-68.92
-26,669,500
9,284,590
0.27%
2023-08-23
WOLVERINE TRADING, LLC
reduced
-71.17
-3,338,190
1,041,810
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-34.78
-1,016,600
1,202,460
0.01%
2023-08-22
Asset Dedication, LLC
unchanged
-
-12,000
57,000
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-16.52
-1,041,320
2,357,610
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
44.27
377,000
2,272,000
0.02%

1–10 of 43

Latest Funds Activity

Are funds buying SRPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SRPT
No. of Funds

Schedule 13G FIlings of Sarepta Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
sands capital management, llc
2.5%
2,151,378
SC 13G/A
Feb 10, 2023
janus henderson group plc
6.9%
6,028,016
SC 13G/A
Feb 09, 2023
vanguard group inc
9.15%
8,033,264
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
5,557,234
SC 13G/A
Feb 14, 2022
sands capital management, llc
6.16%
5,364,627
SC 13G
Feb 11, 2022
janus henderson group plc
8.3%
7,245,862
SC 13G
Feb 10, 2022
vanguard group inc
9.54%
8,311,108
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
6.1%
5,285,234
SC 13G/A
Aug 10, 2021
capital research global investors
4.8%
3,842,491
SC 13G/A

Recent SEC filings of Sarepta Therapeutics

View All Filings
Date Filed Form Type Document
Aug 15, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 08, 2023
4
Insider Trading
Aug 04, 2023
144
Notice of Insider Sale Intent
Aug 02, 2023
S-8
Employee Benefits Plan
Aug 02, 2023
10-Q
Quarterly Report
Jun 22, 2023
8-K
Current Report
Jun 22, 2023
8-K
Current Report

Peers (Alternatives to Sarepta Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.1B
56.0B
3.50% 10.46%
31.22
4.84
-2.31% -31.27%
258.4B
1.8B
-3.35% 26.15%
-149.17
142.72
69.45% 14.65%
91.3B
9.5B
1.11% 26.35%
27.14
9.61
13.83% 5.33%
88.1B
12.7B
-2.05% 20.27%
20.49
6.95
-10.94% -24.40%
21.7B
1.2B
-8.20% -15.77%
-20.42
17.55
39.94% -8.44%
11.2B
1.0B
5.15% 8.54%
-12.29
11.11
20.15% -79.16%
10.5B
2.1B
-3.19% 8.81%
12.04
4.97
18.01% 38.16%
MID-CAP
3.0B
225.6M
0.06% -27.49%
-5.4
13.27
-2.11% 21.02%
2.9B
-
-11.82% 158.82%
-8.93
-
- -28.88%
2.6B
402.9M
1.47% -16.95%
-3.63
6.49
20.50% -42.46%
2.1B
27.2M
-3.08% -49.09%
-2.89
78.22
- -14.43%
SMALL-CAP
3.1B
-
-6.35% -39.40%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-15.88% -2.65%
11.18
4.26
77.72% 112.02%
289.9M
152.5M
-10.34% 48.10%
38.91
1.9
127.84% 103.41%
28.7M
-
0.62% 3389.00%
-0.62
-
- -31.51%

Sarepta Therapeutics News

Best Stocks
Brookstone Capital Management Increases Position in Genuine ....
Best Stocks,
17 hours ago
The Motley Fool
2 Top Growth Stocks to Buy With $500.
The Motley Fool,
7 days ago
Investor Relations | Sarepta Therapeutics, Inc.
Quest Diagnostics Granted FDA Breakthrough Designation for its ....
Investor Relations | Sarepta Therapeutics, Inc.,
22 days ago

Returns for SRPT

Cumulative Returns on SRPT

9.6%


10-Year Cumulative Returns

10.1%


7-Year Cumulative Returns

-4.1%


5-Year Cumulative Returns

-5.8%


3-Year Cumulative Returns

Risks for SRPT

What is the probability of a big loss on SRPT?

99.2%


Probability that Sarepta Therapeutics stock will be more than 20% underwater in next one year

85.8%


Probability that Sarepta Therapeutics stock will be more than 30% underwater in next one year.

39.2%


Probability that Sarepta Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SRPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Sarepta Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Sarepta Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.8%1,003,434,000975,683,000933,013,000876,047,000835,184,000765,786,000701,887,000645,564,000600,082,000573,356,000540,099,000495,074,000450,191,000407,496,000380,833,000365,135,000344,580,000323,441,000301,034,000273,896,000241,364,000
Costs and Expenses-3.2%1,513,229,0001,563,091,0001,469,214,0001,411,228,0001,273,468,0001,160,512,0001,161,597,0001,170,177,0001,227,305,0001,171,358,0001,104,262,0001,118,740,0001,060,379,0001,154,698,0001,086,396,000979,842,000905,796,000712,717,000644,662,000501,308,000444,584,000
  S&GA Expenses-7.3%454,543,000490,295,000451,421,000408,998,000365,338,000283,369,000282,660,000290,651,000304,897,000306,238,000317,875,000313,253,000313,309,000307,014,000284,812,000267,608,000245,223,000224,986,000207,761,000175,762,000150,894,000
  R&D Expenses-----------------436,610,000446,192,000401,843,000300,077,000247,732,000
EBITDA100.0%--1,016,324,000-603,681,000-611,595,000-404,838,000-252,225,000-317,406,000-384,177,000-538,655,000-611,786,000-466,207,000-517,648,000-453,595,000-585,552,000-652,664,000------
EBITDA Margin100.0%--1.04-0.65-0.70-0.48-0.33-0.45-0.60-0.90-1.07-0.86-1.05-1.01-1.44-1.71------
Interest Expenses-38.5%24,455,00039,753,00044,418,00057,495,00055,949,00055,949,00055,949,00053,683,00047,166,00040,721,00034,418,00024,737,00019,307,00012,880,0008,550,0008,894,00010,500,000-11,308,0007,849,0007,432,000
Earnings Before Taxes19.4%-885,019,000-1,098,527,000-689,963,000-710,546,000-502,035,000-355,701,000-418,948,000-485,544,000-634,040,000-703,081,000-553,065,000-599,572,000-529,269,000-654,698,000-713,880,000-620,562,000-571,529,000-403,945,000-362,610,000-246,776,000-215,432,000
EBT Margin100.0%--1.13-0.74-0.81-0.60-0.46-0.60-0.75-1.06-1.23-1.02-1.21-1.18-1.61-1.87------
Net Income18.6%-907,677,000-1,115,218,000-703,488,000-716,225,000-506,631,000-356,555,000-418,780,000-486,116,000-634,471,000-703,886,000-554,128,000-600,514,000-530,341,000-655,924,000-715,075,000-620,267,000-570,334,000-403,198,000-361,918,000-245,021,000-216,362,000
Net Income Margin100.0%--1.14-0.75-0.82-0.61-0.47-0.60-0.75-1.06-1.23-1.03-1.21-1.18-1.61-1.88------
Free Cashflow100.0%--468,325,000-356,170,000-287,346,000-347,721,000-386,868,000-481,662,000-653,275,000-783,194,000-794,926,00025,264,00047,357,000233,986,000265,072,000-516,094,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets2.2%3,1263,0603,1283,1562,9973,0563,1482,6622,7592,7652,9852,7812,8832,9471,8231,7021,7481,9641,6421,1831,247
  Current Assets-0.6%2,4732,4882,5582,6262,4692,5312,6042,1852,2652,2712,4852,3232,4592,5471,4691,3621,4271,6711,4261,0121,139
    Cash Equivalents-2.3%8528729671,0398691,2342,1161,5991,6971,4821,5031,4751,6401,764835725809732371210410
  Inventory11.9%227203204221208199186288269240232220180173171166157140125116104
  Net PPE3.3%18918318018118318719119920320319017215313713012011710697.0077.0058.00
Liabilities1.6%2,3842,3472,7432,7252,2702,1992,2202,1932,2742,2302,2231,8891,8401,8031,005707649615610543548
  Current Liabilities-7.1%499537620603546455453373425365416378355306265216162137174114105
Shareholder's Equity4.0%7417133854317268579284704855357628921,0431,1458189951,0991,3491,032640699
  Retained Earnings-0.5%-4,450-4,426-3,910-3,800-3,543-3,311-3,206-3,084-3,036-2,955-2,848-2,658-2,462-2,311-2,294-2,058-1,931-1,655-1,578-1,438-1,361
  Additional Paid-In Capital1.0%5,1935,1404,2974,2354,2724,1694,1353,5543,5223,4913,6103,5513,5053,4563,1123,0533,0313,0042,6112,0782,061
Accumulated Depreciation----------------45.0038.0033.0028.0025.0022.00
Shares Outstanding0.1%93.0093.0088.0088.0088.0087.0087.0080.0080.0080.0079.0079.0077.0076.0074.0075.0074.0074.0066.0067.0066.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-12.8%-488-433-325-262-321-363-443-588-702-700107118289318-456-415-460-499-388-297-241
  Share Based Compensation-22.7%19024523321218911511411411411310810194.0086.0079.0069.0060.0056.0050.0045.0040.00
Cashflow From Investing155.5%138-248-1,046-1,059-1,058-44749537440853.00-12119.00-52.7813428732.00-13.53-221-370-626-438
Cashflow From Financing1.7%335329233771560564562339352366682612595584643907881900530516922

SRPT Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Products, net$ 238,988$ 211,237$ 470,483$ 400,062
Type of Revenue [Extensible List]  us-gaap:ProductMemberus-gaap:ProductMember
Collaboration22,25022,250$ 44,255$ 44,255
Total revenues261,238233,487514,738444,317
Cost and expenses:    
Cost of sales (excluding amortization of in-licensed rights)34,12437,79569,14169,238
Research and development241,890252,329487,569446,579
Selling, general and administrative118,564154,316229,278226,156
Amortization of in-licensed rights179179357357
Total cost and expenses394,757444,619786,345742,330
Operating loss(133,519)(211,132)(271,607)(298,013)
Other loss, net:    
Gain from sale of Priority Review Voucher102,0000102,0000
Loss on debt extinguishment00(387,329)0
Other income (expense), net16,934(16,961)29,641(34,226)
Total other (loss), net118,934(16,961)(255,688)(34,226)
Loss before income tax expense (benefit)(14,585)(228,093)(527,295)(332,239)
Income tax expense (benefit)9,3553,38813,4004,267
Net loss(23,940)(231,481)(540,695)(336,506)
Other comprehensive income (loss):    
Unrealized gains (losses) on investments, net of tax(636)(2,179)609(2,465)
Total other comprehensive income (loss)(636)(2,179)609(2,465)
Comprehensive loss$ (24,576)$ (233,660)$ (540,086)$ (338,971)
Net loss per share - basic$ (0.27)$ (2.65)$ (6.11)$ (3.85)
Net loss per share - diluted$ (0.27)$ (2.65)$ (6.11)$ (3.85)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share88,74387,51188,46687,383
Weighted average number of shares of common stock used in computing basic and diluted net loss per share88,74387,51188,46687,383

SRPT Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 851,929$ 966,777
Short-term investments1,008,7861,022,597
Accounts receivable236,808214,628
Inventory226,876203,968
Other current assets148,215149,891
Total current assets2,472,6142,557,861
Property and equipment, net188,874180,037
Right of use assets134,72864,954
Non-current inventory166,635162,545
Other non-current assets163,039162,969
Total assets3,125,8903,128,366
Current liabilities:  
Accounts payable109,79695,875
Accrued expenses326,877418,996
Deferred revenue, current portion44,98989,244
Other current liabilities16,99215,489
Total current liabilities498,654619,604
Long-term debt1,235,5171,544,292
Lease liabilities, net of current portion129,17057,578
Deferred revenue, net of current portion485,000485,000
Contingent consideration36,10036,900
Other non-current liabilities3842
Total liabilities2,384,4792,743,416
Commitments and contingencies (Note 16)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding00
Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,273,541 and 87,950,117 issued and outstanding at June 30, 2023, and December 31, 2022, respectively99
Additional paid-in capital5,193,3884,296,841
Accumulated other comprehensive loss, net of tax(1,055)(1,664)
Accumulated deficit(4,450,931)(3,910,236)
Total stockholders’ equity741,411384,950
Total liabilities and stockholders’ equity$ 3,125,890$ 3,128,366
Douglas S. Ingram
840
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.